💊 医薬品 A-Z 🧬 標的 🛠 ツール 📚 ガイド
全医薬品 薬物分類 治療領域 副作用
ガイド 用語集 年表
比較 薬物の体内の旅 薬物ファミリー
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Afatinib

CHEMBL1173655 Phase 4 承認済み Small molecule
Half-Life
37 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
485.9 g/mol
LogP
3.6
Phase
4

A targeted cancer medicine that blocks certain proteins called EGFR and HER2 that drive the growth of some cancers. By permanently binding to and shutting down these signaling proteins, afatinib helps slow or stop tumor growth in cancers where these targets are overactive.

分子量

485.9400 g/mol

LogP

3.60

TPSA

88.60 Ų

リピンスキーの五則

適合

治療領域

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Endometriosis Cardiovascular Disease Respiratory Disease Non-Small Cell Lung Cancer Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Infectious Disease Melanoma Gastroesophageal Reflux Disease Inflammatory Bowel Disease Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Lymphoma Breast Cancer Prostate Cancer Colorectal Cancer Leukemia

薬物分類

L — L - Antineoplastic and Immunomodulating Agents

作用機序

Irreversible covalent inhibitor of ErbB family (EGFR/HER1, HER2, HER4) tyrosine kinases.

Pharmacokinetics (PK)

Half-Life 37 hours

Pharmacodynamics (PD)

機序

Irreversible covalent inhibitor of ErbB family (EGFR/HER1, HER2, HER4) tyrosine kinases.

2D構造

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1

                

                

                
                

                    
InChI

                    
InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C24H25ClFN5O3

                    

                    
                    

                        
HBD / HBA

                        
2 / 8

                    

                    
                    

                        
回転可能結合数

                        
8

                    

                    
                    
                    

                        
重原子数

                        
34

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
よくある質問

                

                    
                    

                        
                        

                            
A targeted cancer medicine that blocks certain proteins called EGFR and HER2 that drive the growth of some cancers. By permanently binding to and shutting down these signaling proteins, afatinib helps slow or stop tumor growth in cancers where these targets are overactive.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Irreversible covalent inhibitor of ErbB family (EGFR/HER1, HER2, HER4) tyrosine kinases.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Afatinib: Half-life: 37 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Afatinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Methotrexate
                            Small molecule
                        
                        
                        
                            Tamoxifen
                            Small molecule
                        
                        
                        
                            Cyclosporine
                            Protein
                        
                        
                        
                            Tacrolimus
                            Small molecule
                        
                        
                    

                

                

                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1173655.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 10184653.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
医学的免責事項

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.